Status:

COMPLETED

Evaluate Initial Safety of the HemiBridge™ System in Guided Spinal Growth Treatment of Progressive Idiopathic Scoliosis

Lead Sponsor:

SpineForm LLC

Collaborating Sponsors:

Children's Hospital Medical Center, Cincinnati

University Hospitals Cleveland Medical Center

Conditions:

Scoliosis

Eligibility:

All Genders

10+ years

Phase:

NA

Brief Summary

The purpose of this clinical trial is to study a new method of treatment for patients who are diagnosed with idiopathic scoliosis and have abnormal and increasing curvature of the spine. The treatment...

Detailed Description

Significance Spinal deformity fusion treatment involves some of the most costly and invasive procedures in orthopaedics. The development of an effective treatment method to avoid fusion is needed. Man...

Eligibility Criteria

Inclusion

  • \- Patients must meet all the criteria to be enrolled in this study:
  • Trial subject population will involve patients who are skeletally immature, who have a diagnosis of idiopathic scoliosis with a single main thoracic curve Cobb angle 25° to 40° and Lenke Type 1A or 1B.
  • Chronologic age:
  • Males ≥ 10 years
  • Females ≥ 10 years
  • Females pre-menarchal at screening examination
  • Bone age as confirmed by radiographs of left hand and wrist according to the "Atlas Matching" method of Greulich and Pyle:
  • Females: ≥ 8 years and 10 months not to exceed 13 years
  • Males: ≥ 10 years not to exceed 15 years
  • Skeletal immaturity (Risser grade 0 and the triradiate cartilage is open) as determined by standing, upright PA radiograph. If radiographic Risser grade results are indeterminate, the bone age from the Atlas Matching will prevail.
  • Main thoracic Cobb angle of 25° to 40° as determined from standing, upright PA radiographs where the end vertebra are between or including T3 and L1 without wearing a brace
  • Clinical diagnosis of idiopathic scoliosis with a single main thoracic curve as determined with measurement on standing posterior- anterior PA radiographs.
  • Defined as a single thoracic curve where either: central sacral vertical line (CSVL) passes between the pedicles of the apical lumbar vertebra; or the CSVL touches the lumbar apical body(ies) (Lenke Type 1A or 1B, respectively)
  • Achievable anatomical fit as determined by calibrated standing PA film:
  • Disc height not exceeding 10 mm at each spinal level to be instrumented relative to location of the probable implant and
  • Minimum central vertebral height that will accept the selected HemiBridge™ Clip size at all levels planned for implants
  • BMI \< 30
  • Physical and mental ability to undergo surgery with single lung ventilation
  • Written informed assent from the patient
  • Written informed consent from parent and/or legal guardian and authorization to use protected health information (by Sponsor, third party core lab and/or clinical evaluation committee)

Exclusion

  • Patients who meet any of the exclusion criteria will not be enrolled.
  • Non-idiopathic scoliosis
  • Males and females chronological age \< 10 years
  • Triradiate cartilage is closed as determined on the standing PA radiograph at baseline screening
  • Any curve type that does not meet definition of Lenke 1A or 1B
  • Any main thoracic deformity that measures \< 25° or \> 40° Cobb angle
  • Any main thoracic deformity that includes vertebral levels including and cranial to T2
  • Any main thoracic deformity that includes vertebral levels including and caudal to L2
  • Prior thoracotomy, thoracostomy or any spine surgery
  • T3-T12 kyphosis \> 40° (T4 or T5-T12 if visualization impaired at T3)
  • Known history or existing malignancy, or any systemic or local infection
  • Spinal cord abnormalities that require treatment
  • Presence of neurological deficit (motor grades 0-4, sensory grades 0-1, reflexes grade 0 or 5 or asymmetry of deep tendon reflexes \> 2 from right to left)
  • Insulin-dependent diabetes
  • Severe asthma
  • Reduced pulmonary function, defined as \< 60% of predicted value (Forced expiratory volume in one second \[FEV1\] divided by forced vital capacity \[FVC\]) or Subject has moderately severe or worse ventilatory limitation defined as \< 60% of predicted value of the forced vital capacity \[FVC\] for age, race, sex and height (with height determined by arm span in patients with scoliosis and reference equations derived from the data of Wang et al 199329.)
  • Cardiopulmonary or other systemic disease
  • Bleeding disorder(s)
  • Ataxia
  • Documented HIV or hepatitis infection
  • Family history of neurofibromatosis or Marfan's syndrome
  • Medical contraindication to anesthesia
  • Suspected or known allergy to titanium
  • Not available for interval visits and long term follow-up exams

Key Trial Info

Start Date :

August 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 29 2017

Estimated Enrollment :

6 Patients enrolled

Trial Details

Trial ID

NCT01465295

Start Date

August 1 2011

End Date

December 29 2017

Last Update

February 5 2018

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229

2

University Hospitals Case Medical Center - Rainbow Babies & Children's Hospital

Cleveland, Ohio, United States, 44115